title: Lingual lesions with orally disintegrating risperidone.
authors.forename: Nanette M
authors.initials: NM
authors.lastname: Dowling
authors.forename: James L
authors.initials: JL
authors.lastname: Megna
authors.forename: Andrew
authors.initials: A
authors.lastname: Burgdorf
authors.forename: Veena
authors.initials: V
authors.lastname: Yashaswi
mesh_terms: D000042:Absorption; D000284:Administration, Oral; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D005260:Female; D006801:Humans; D008297:Male; D009061:Mouth Mucosa / Q000378:metabolism; D011618:Psychotic Disorders / Q000188:drug therapy; D018967:Risperidone / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D014060:Tongue Diseases / Q000139:chemically induced*
chemical_list: D014150:Antipsychotic Agents; D018967:Risperidone